#### SCIENCEDOMAIN international www.sciencedomain.org



# SDI Review Form 1.6

Journal Name:	International Neuropsychiatric Disease Journal
Manuscript Number:	Ms_INDJ_44483
Title of the Manuscript:	N-acetylcysteine in psychiatric disorders: possible role of cysteinet deregulation
Type of the Article	

## General guideline for Peer Review process:

This journal's peer review policy states that <u>NO</u> manuscript should be rejected only on the basis of '<u>lack of Novelty'</u>, provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

## **PART 1:** Review Comments

	Reviewer's comment	Author's comment (if agreed highlight that part in the manu- his/her feedback here)
Compulsory REVISION comments		
Minor REVISION comments	Citations should be indicated as per the guidelines (the reference number in brackets [3].) <b>Page 1</b> ,Introduction- the word 'specifically' in line 17, and the word 'indeed; in line 19 & the word 'Finally; in line 25 does not seem to be necessary. Line 20 & 21: NAC improved the baseline anxiety and depression scores, as well as the use of antidepressant medications- Can this statement be made more clear or reframed? Line 22,23: NAC has also shown beneficial effects in schizophrenia (treatment of schizophrenia?) Lines 36 to 38: sentence is too long, needs to be reframed <b>Page 2</b> , line 3: it has been reported that a 38-year-old Line 49: In fact, a recent clinical trial has confirmed that NAC has therapeutic action in patients with Parkinson's disease [28]. How would the role of SCCPs be explained here? Line 55,56: reference? <b>Page 3:</b> Line 7- effects Line 16: It has been well established that NAC can cross the blood-brain barrier having effects in the CNS (in animal models or human studies or both?)	
Optional/General comments	On the whole it is an interesting short review article which aims at understanding cysteinet deregulation in psychiatric disorders and the therapeutic role of NAC in these disorders	

# <u>PART 2:</u>

		Author's comment (if agreed highlight that part in the manus his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

# **Reviewer Details:**

Name:	Liegelin Kavitha Bernhardt
Department, University & Country	Manipal Academy of Higher Education, India

ed with reviewer, correct the manuscript and nuscript. It is mandatory that authors should write

d with reviewer, correct the manuscript and uscript. It is mandatory that authors should write